Sun Pharma has expanded its horizons by acquiring Organon, a notable New Jersey pharmaceutical firm. This strategic acquisition fortifies S...

Sun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...

US company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...

Shares of Suzlon Energy fell 3% to Rs 25 in Wednesday's trade on BSE after the Sun Pharma promoter Dilip Shanghvi and Associates decided to...

With the termination of the agreement, the investor group's nominee director on Suzlon's board, Hiten Timbadia, has also resigned with effe...

The issue price includes the warrant subscription price (Rs. 44.50 per warrant) and the warrant exercise price (Rs. 133.50 per warrant).

Sebi had initiated a probe against Sun Pharma, its managing director Dilip Shanghvi and its directors on the basis of two whistleblower com...

The decision to abandon plans to set up a payments bank was taken as the promoters felt that they lacked adequate physical presence in term...

The deal, announced in February this year, would see Shanghvi acquiring at least 23 per cent stake in Suzlon which has been grappling with ...

Sun Pharma rose as much as 2.8 per cent to hit its intraday high of Rs 1066.40 on the BSE, after ET NOW reported the story.

Troubled shipbuilder ABG Shipyard is looking for a white knight and it's now pinning hopes on India's richest man Dlilip Shanghvi for a bai...

Suzlon Energy last week signed definitive agreements with Dilip Shanghvi Family and Associates (DSA) for equity investments of Rs 1,800 cro...

This weekend, Shanghvi announced a Rs 1,400-crore investment to pick up 23% stake in ailing renewable energy company Suzlon through DSA.

The open offer price for 157.64 crore shares is Rs 18 per scrip, a total of about Rs 2,837.52 crore.

Suzlon’s promoters will retain management control “by virtue of pooling arrangement for voting”, while the Shanghvi family will remain a fi...

Dilip S Shanghvi expects the Ranbaxy deal to be concluded by middle of next month while stating that the key challenge before the combined ...

A master strategist, Dilip Shanghvi, promoter of Sun Pharma and ET’s business leader for 2014, has come a long way from the time he built h...